Evidence map›Paper›PMID 22912552›Full record

Trial reportWorld journal of gastroenterology2012

Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome.

Philippe Ducrotté, Prabha Sawant, Venkataraman Jayanthi

3 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 131 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 10 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05194033 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 1)

TypeinterventionalSponsorPeking UniversityRan2022 to 2022Enrolled31ConditionsSARS-CoV-2ArmsProbiotics daily, Placebo daily
NCT05195047 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 2)

TypeinterventionalSponsorPeking UniversityRan2022 to 2022Enrolled44ConditionsSARS-CoV-2Arms1 week placebo(Week 1), 1 week of probiotics(Week 1), 1 week placebo(Week 2), 1 week of probiotics(Week 2), 1 week placebo(Week 3)
NCT06521879 nacompletednot on this mapstarted 2022, after this paper: background citation

Improved Gastrointestinal Tolerance and Iron Status Via Probiotic Use in Iron Deficiency Anemia Patients Initiating Oral Iron Replacement

TypeinterventionalSponsorAntalya Training and Research HospitalRan2022 to 2023Enrolled295ConditionsIron Deficiency Anemia Treatment, Iron Deficiency AnemiaArmsLactobacillus plantarum 299v probiotic support
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 10 syntheses or guidelines pooled it, 255 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Pooled it
  11. Trial
  12. Safety ofNutrients · 2026
    Trial
  13. Trial
  14. Efficacy and dose response ofWorld journal of gastroenterology · 2023
    Trial
  15. Trial
  16. Effect of Oral Intake ofNutrients · 2022
    Trial
  17. Trial
  18. Trial
  19. The Effect ofNutrients · 2020
    Trial
  20. Trial

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Philippe DucrottéDepartment of Gastroenterology (Inserm UMR-1073), Rouen University Hospital and Rouen University, 76031 Rouen Cedex, France. philippe.ducrotte@chu-rouen.fr
Prabha Sawant
Venkataraman Jayanthi
Université de Rouen Normandie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the symptomatic efficacy of Lactobacillus plantarum 299v (L. plantarum 299v) (DSM 9843) for the relief of abdominal symptoms in a large subset of irritable bowel syndrome (IBS) patients fulfilling the Rome III criteria.

methodsIn this double blind, placebo-controlled, parallel-designed study, subjects were randomized to daily receive either one capsule of L. plantarum 299v (DSM 9843) or placebo for 4 wk. Frequency and intensity of abdominal pain, bloating and feeling of incomplete rectal emptying were assessed weekly on a visual analogue scale while stool frequency was calculated.

resultsTwo hundred and fourteen IBS patients were recruited. After 4 wk, both pain severity (0.68 + 0.53 vs 0.92 + 0.57, P < 0.05) and daily frequency (1.01 + 0.77 vs 1.71 + 0.93, P < 0.05) were lower with L. plantarum 299v (DSM 9843) than with placebo. Similar results were obtained for bloating. At week 4, 78.1 % of the patients scored the L. plantarum 299v (DSM 9843) symptomatic effect as excellent or good vs only 8.1 % for placebo (P < 0.01).

conclusionA 4-wk treatment with L. plantarum 299v (DSM 9843) provided effective symptom relief, particularly of abdominal pain and bloating, in IBS patients fulfilling the Rome III criteria.

Indexed as

Lactiplantibacillus plantarumAdultDouble-Blind MethodFemaleHumansIrritable Bowel SyndromeMaleMiddle AgedProbioticsSeverity of Illness IndexYoung AdultAbdominal painClinical trialIrritable bowel syndromeLactobacillus plantarum 299vProbiotics

Identifiers

PMID22912552
PMCPMC3419998
OpenAlexW2120352579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.